Compare Gilead Sciences, Inc. (GILD) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Qurate Retail Inc Series A — how do they compare? Gilead Sciences, Inc. trades at $132.96 (market cap $163.51B), while Qurate Retail Inc Series A trades at $0.07 (market cap $768.68K). The key difference: Gilead Sciences, Inc. is far larger — about 212715.3× Qurate Retail Inc Series A's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Qurate Retail Inc Series A pays none. Which is the better fit depends on your goals.
| GILD | QVCAQ | |
|---|---|---|
Market Cap | $163.51B | $768.68K |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $15.03 |
52-Week Low | $108.22 | $0.07 |
Enterprise Value | $178.05B | $4.73B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
QVCAQ trades at $0.088, up 7.32% today but remains deeply distressed with negative shareholder equity of -$971 million. The stock shows a bearish technical signal with 13 sell indicators versus 3 buys. Fundamentally, the company reported a $2.44 billion net loss in 2025 despite $9.23 billion revenue, with negative profit margins and declining revenue trends. Recent news highlights QVC celebrating 40 years of live shopping innovation through TikTok Shop collaborations.
The outlook remains highly risky due to persistent losses, negative equity, and deteriorating balance sheet. While the low P/E of 7.42 and P/B of 0.33 suggest deep value, the negative ROE of -56.13% and mounting debt-to-asset ratio of 77.57% indicate severe financial stress. Investment opportunity exists only for speculative turnaround bets, with bankruptcy risk being substantial given the negative cash flow trends and declining asset base.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
